0.00Open5.07Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV2.37%PremiumDec 20, 2024Expiry Date4.89Intrinsic Value100Multiplier-2DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Phathom Pharmaceuticals Stock Discussion
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
No comment yet